Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Medtronic
Dow
Healthtrust
US Department of Justice
McKesson
Argus Health
Fuji
US Army
McKinsey

Generated: October 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,880,631

« Back to Dashboard

Summary for Patent: 4,880,631

Title: Controlled porosity osmotic pump
Abstract:The instant invention is directed to an osmotic pump, for the controlled release of diltiazem L-malate to an environment of use, said pump comprising: (A) a core which comprises a therapeutically effective amount of diltiazem L-malate and an effective buffering amount of sodium bitartrate surrounded by (B) a rate controlling water insoluble wall, having a fluid permeability of 6.96.times.10.sup.-18 to 6.96.times.10.sup.-14 cm.sup.3 sec/g and a reflection coefficient of less than 0.5, prepared from: (i) a polymer permeable to water but impermeable to solute and (ii) 0.1 to 60% by weight, based on the total weight of (i) and (ii), of at least one pH insensitive pore forming additive dispersed throughout said wall.
Inventor(s): Haslam; John L. (Lawrence, KS), Rork; Gerald S. (Lawrence, KS)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:07/100,665
Patent Claim Types:
see list of patent claims
Delivery; Device; Composition;

No matches for this query

International Patent Family for Patent: 4,880,631

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark529188► Subscribe
European Patent Office0309051► Subscribe
Spain2039275► Subscribe
Greece3004364► Subscribe
Hong Kong47493► Subscribe
Ireland882899► Subscribe
Ireland62747► Subscribe
Germany3869032► Subscribe
Canada1320885► Subscribe
Israel87756► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Julphar
UBS
Express Scripts
Cipla
Baxter
Chinese Patent Office
Accenture
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot